Oligometastases After Curative Esophagectomy Are Not One Size Fits All

Area of Science:

• Oncology
• Surgical Oncology
• Cancer Recurrence Research

Background:

• Esophagectomy for esophageal cancer has a high recurrence rate, exceeding 50%.
• Oligometastasis, defined as isolated recurrence before widespread disease, presents a target for intervention.
• Understanding recurrence site patterns is crucial for treatment strategy.

Purpose of the Study:

• To investigate the clinical presentation and prognosis of esophageal cancer recurrence at different solid organ sites.
• To compare outcomes among patients with isolated liver, lung, or brain oligometastasis after esophagectomy.

Main Methods:

• Retrospective analysis of 104 patients with isolated solid organ recurrence (liver, lung, brain) post-R0 esophagectomy (1995-2016).
• Comparison of clinicopathologic characteristics and outcomes across recurrence sites.
• Overall survival analysis using Kaplan-Meier and Cox proportional hazards models.

Main Results:

• Lung oligometastasis showed significantly longer median overall survival (2.41 years) compared to brain (0.95 years) and liver (0.95 years).
• Most liver (80%), brain (51%), and lung (44%) oligometastases occurred within 12 months post-esophagectomy.
• The survival benefit for lung oligometastasis persisted after adjusting for patient and tumor characteristics.

Conclusions:

• Esophageal cancer recurrence presentation and prognosis differ significantly by the site of metastasis.
• Lung oligometastases are associated with a more indolent disease course.
• Tailored treatment strategies, potentially more aggressive for lung oligometastases, are warranted over a standardized palliative approach.